Ophthalmic Surg Lasers Imaging Retina. 2023 Jul;54(7):388-394. doi: 10.3928/23258160-20230522-02. Epub 2023 Jun 1.
To compare the risk factors for the development and progression of pigmentary retinopathy in patients exposed to pentosan polysulfate sodium (PPS).
Retrospective cohort study of patients exposed to PPS with at least two follow-up visits with multimodal imaging.
A total of 97 patients were included (33 with PPS-associated retinopathy and 64 without). The average follow-up was 29.4 months, overall cumulative dose was 1,220 ± 910 g (1,730 ± 870 vs 959 ± 910; < 0.0001), and total PPS duration was 12.1 ± 7.1 years (16.0.2 ± 6.1 vs 10.1 ± 6.9; < 0.0001). The best-corrected visual acuity remained stable during follow-up. At presentation, the average area of the retinopathy in the worse eye was 54.1 ± 50 mm in the PPS-retinopathy group, worsening at a rate of 6.10 ± 10 mm/year. Patients who developed choroidal neovascular membranes (CNVMs) had faster rates of retinopathy progression (11.6 ± 12 vs 3.53 ± 7.6 mm/year, = 0.036). No patient had the exact same gene mutation.
PPS-associated pigmentary retinopathy can continue to progress over time, even after discontinuing the medication. CNVM development may be associated with faster rates of retinopathy progression. .
比较暴露于聚戊烯糖硫酸钠（PPS）的患者发生和进展为色素性视网膜病变的危险因素。
对至少两次接受多模态成像随访的暴露于 PPS 的患者进行回顾性队列研究。
共纳入 97 例患者（33 例患有 PPS 相关性视网膜病变，64 例无）。平均随访时间为 29.4 个月，总累积剂量为 1220±910 g（1730±870 与 959±910；<0.0001），总 PPS 持续时间为 12.1±7.1 年（16.0±6.1 与 10.1±6.9；<0.0001）。最佳矫正视力在随访期间保持稳定。在就诊时，病变更严重的眼的视网膜病变平均面积为 PPS 视网膜病变组 54.1±50mm，每年恶化 6.10±10mm。发生脉络膜新生血管膜（CNVM）的患者视网膜病变进展速度更快（11.6±12 与 3.53±7.6mm/年，=0.036）。没有患者具有完全相同的基因突变。
即使停止用药，PPS 相关性色素性视网膜病变也会随时间持续进展。CNVM 发生可能与视网膜病变进展更快有关。
